

Original Research Article

<https://doi.org/10.20546/ijcmas.2018.709.111>

A Study of Uropathogenic ESBL Producing Gram Negative Bacilli in a Teaching Hospital

Gitanjali Kailas Badave, Qader Ahmed Jalily* and G. Sasikala

Department of Microbiology, Mahavir Institute of Medical Sciences, #2-4-40, Shivareddypet, Vikarabad, Ranga Reddy - 501 101, Telangana, India

*Corresponding author

ABSTRACT

About 150 million people suffer from urinary tract infection each year. In majority of cases, treatment is initiated empirically based on the antimicrobial resistance pattern of the urinary pathogens prevalent in a particular setting. Emerging antibiotic resistance among *Enterobacteriaceae* has posed challenges in choosing empiric regimens. Therefore, the present study was designed to identify etiological agents of urinary tract infections, detect ESBL producing uropathogens and study their antibiotic resistance profile. Around 306 urine (Midstream urine and catheterized) samples were collected and processed by semi-quantitative culture on Cysteine Lactose Electrolyte Deficient media, blood agar, and MacConkey agar by standard loop method. Bacterial colony count more than 10^5 colony-forming units (CFU)/ml was taken as significant bacteriuria. Antibiotic sensitivity testing was done by Kirby-Bauer disc diffusion method as per Clinical and Laboratory Standards Institute guidelines. ESBL screening and phenotypic confirmation was done by testing the strain against ceftazidime and ceftazidime/clavulanic acid, cefotaxime and cefotaxime/clavulanic acid). Out of 306 urine samples collected, significant bacteriuria was observed in 92.1% (282/306) samples. Out of the culture positive 282 specimens, female patients reported 72.4% growth whereas male patients reported 27.6% growth. Out of 282 isolates, 96.1% isolates were Gram-negative, *E. coli* being predominant isolate whereas 3.9 % were Gram-positive isolates (including *Candida* spp). The isolates showed least resistance to Imipenem (12%), followed by Nitrofurantoin (24%), Gentamicin (28%) Piperacillin Tazobactam (36%). Higher resistance was reported for Norfloxacin (80%), Cefazolin (76%), and Cotrimoxazole (68%) Ciprofloxacin (64%), Tetracycline (60%). Among the Gram negative isolates, 40.2% (109/271) were found to be ESBL producers.

Keywords

Uropathogens, Extended-spectrum beta-lactamase (ESBL), Gram negative, Community acquired infection, Hospital acquired infection

Article Info

Accepted:

08 August 2018

Available Online:

10 September 2018

Introduction

About 150 million people suffer from urinary tract infection (UTI) each year (Flores-Mireles *et al.*, 2015). Although UTI's occur in all age groups including men and women, clinical studies suggest that the overall prevalence of UTI is higher in women (Salvatore S *et al.*, 2011) *Escherichia coli* is the most common

cause of (80–85%) of community-acquired urinary tract infections (Nicolle *et al.*, 2008). Rarely UTI may be due to viral or fungal infections (Amdekar *et al.*, 2011). Healthcare-associated urinary tract infections mainly from urinary catheterization involve a much broader range of pathogens including *E. coli*, *Klebsiella* spp, *Pseudomonas aeruginosa*, *Proteus* spp, *Candida albicans*, and

Enterococcus faecalis etc. (Sievert *et al.*, 2013; Bagshaw *et al.*, 2006) In majority of cases, treatment is initiated empirically based on the antimicrobial resistance pattern of the urinary pathogens prevalent in a particular setting. The time required for culture results often exceeds the time to clinical cure with empiric treatment, therefore, in almost all cases of UTI empirical antimicrobial treatment is initiated before the laboratory results of urine culture are available, contributing to increasing antimicrobial resistance due to misuse of antimicrobials (Wilson *et al.*, 2004; Newell *et al.*, 2000). Increasing multidrug resistance in bacterial uropathogens is an important and evolving public health challenge.

The serious increase in the prevalence of extended-spectrum beta lactamases (ESBL's) worldwide creates a need for effective and easy to perform screening methods for detection (Prakash *et al.*, 2013, Yazdi M *et al.*, 2012; Naiemi *et al.*, 2009). ESBL producing organisms are those that hydrolyze the oxyimino beta-lactams and monobactams, but have no effect on the cephamycins and carbapenems. Also, the ESBL producers often also have resistance determinants to other antibiotic groups, leaving an extremely limited range of effective agents (Mukherjee *et al.*, 2013). Detection of ESBL producers from urine specimens is essential because of transfer of drug resistant organisms to other patients. (Aggarwal *et al.*, 2009)

Clinicians have tended to ignore the clinical importance of UTIs despite their significant prevalence, cost, morbidity, and increasing management problems. The reason is largely our opinion that uncomplicated UTIs are common yet not a serious problem, easy to diagnose, and effortless to treat. Antibiotic-resistant organisms causing UTI include Methicillin-resistant *Staphylococcus aureus* (MRSA), Methicillin-resistant coagulase-

negative staphylococci (MRCoNS), vancomycin-resistant enterococci (VRE) and multidrug resistant Gram negative organisms. *Candida* species are frequently found as a colonizing organism and account for few clinical cases of UTI (Neal *et al.*, 2008).

Recent guidelines from the Infectious Diseases Society of America recommended that empiric antibiotic therapy for UTIs should be based on local resistance data, drug availability, and antibiotic intolerance/allergy history of treated patients. (Gupta *et al.*, 2011; Hooton *et al.*, 2010) For uncomplicated cystitis, nitrofurantoin or trimethoprim-sulfamethoxazole (TMP-SMX, if local resistance $\leq 20\%$) can be used empirically, while fluoroquinolones, ceftriaxone, aminoglycosides, and carbapenems are appropriate for pyelonephritis and complicated UTI. Emerging antibiotic resistance among *Enterobacteriaceae* has posed challenges in choosing empiric regimens, especially in infections due to multidrug-resistant (MDR) *Enterobacteriaceae* (Sanchez *et al.*, 2012) in the past decade, emerging resistance among the *Enterobacteriaceae* due to ESBL has been reported worldwide. (Qi *et al.*, 2010) Therefore, regularly updated surveillance of local microbial prevalence and resistance patterns are needed to guide the empiric therapy for UTIs. Therefore, the present study was designed to identify etiological agents of urinary tract infections, detect ESBL producing uropathogens and study their antibiotic resistance profile.

Objectives

To isolate and identify uropathogenic gram negative bacilli.

To determine the antibiotic resistance profile of the isolates

To detect ESBL gram negative isolates

As a baseline study to formulate hospital antibiotic policy and empirical treatment.

Materials and Methods

Type of study: Prospective study

Duration of the study: March 2018 to June 2018

Place of the study: Department of Microbiology, Mahavir Institute of Medical Sciences

Inclusion criteria

Patients suggestive of symptoms of UTI – fever, burning micturation, frequency or urgency of urination, suprapubic discomfort, gross hematuria

Fever with pyuria and/or imaging evidence of UTI (cystitis, pyelonephritis, etc.)

Patients with urinary catheters and suggestive of UTI

Exclusion criteria

Patients with sexually transmitted infections, cervicitis, and vulvovaginitis (can present with symptoms similar to cystitis)

Patients with history of antibiotic therapy for UTI before sending specimen for culture

Patients not willing to participate in the study

Around 306 patients with the inclusion criteria were screened in the present study. The details of patient including name, age, gender, ward (for admitted cases) and brief clinical history were noted. Midstream urine (MSU) sample was collected in sterile, wide mouth, leakproof container and transported immediately to Microbiology laboratory. Catherized urine

samples were collected as per standard guidelines. Semi-quantitative culture of urine was done on Cysteine Lactose Electrolyte Deficient (CLED) media, blood agar, and MacConkey agar by standard loop method. The culture plates were incubated at 37°C for 18-24 h under aerobic conditions. Identification of bacterial growth was confirmed by standard microbiological techniques (Forbes *et al.*, 2007; Collee *et al.*, 2008). Bacterial colony count more than 10⁵ colony-forming units (CFU)/ml was taken as significant bacteriuria.

Antibiotic sensitivity testing was done by Kirby–Bauer disc diffusion method on Mueller-Hinton agar, as per Clinical and Laboratory Standards Institute guidelines. (Bauer *et al.*, 1966; Clinical and Laboratory Standards Institute 2017) Antibiotic discs were procured from HiMedia, Mumbai, India. ESBL screening and phenotypic confirmation was done by testing the strain against ceftazidime and ceftazidime/clavulanic acid, cefotaxime and cefotaxime/clavulanic acid). A difference of >5 mm diameter of the zone of inhibition for combination disc in comparison to the ceftazidime/cefotaxime alone was considered as indicative of ESBL production. *Escherichia coli* ATCC 25922 for ESBL negative and *Klebsiella pneumoniae* 700603 for ESBL positive was used as reference strains. (Clinical and Laboratory Standards Institute 2017)

Results and Discussion

A total of 306 urine samples were collected from 82 male and 224 female patients. Significant bacteriuria was observed in 92.1% (282/306) samples. Out of the culture positive 282 specimens, female patients reported 72.4% growth whereas male patients reported 27.6% growth. Gender wise distribution of specimens and culture positivity is mentioned in Table 1. Out of 282 isolates, 96.1% isolates

were Gram-negative, *E. coli* being predominant isolate whereas 3.9 % were Gram-positive isolates (including *Candida* spp) as mentioned in Table 2.

The isolates showed least resistance to Imipenem (12%), followed by Nitrofurantoin (24%), Gentamicin (28%) Piperacillin Tazobactam (36%). Higher resistance was reported for Norfloxacin (80%), Cefazolin (76%), and Cotrimoxazole (68%) Ciprofloxacin (64%), Tetracycline (60%). The details of antimicrobial sensitivity are mentioned in Table 3. Among the Gram negative isolates, 40.2% (109/271) were found to be ESBL producers (Table 4).

A total of 282 urine cultures were reported positive, 204 (72.4%) females and 78 (27.6%) male patients. Various research studies also conclude that UTI are more common in females as compared to males (Daniele *et al.*, 2011, Dash *et al.*, 2013).

Most of the uropathogenic bacteria are from the host's own gut flora and enter the bladder via the urethra. Shorter urethra in females as compared to males, with its proximity to anus, facilitates the bacteria to ascend in the urinary tract. (Yamamoto *et al.* 1997, Mitsumori *et al.*, 1997) Also, sexually active women have an increased risk of UTI. About 20% of young women with a first UTI will have a recurrent infection. (Scholes *et al.*, 2000)

Of the total 282 uropathogen isolates, *Escherichia coli* was the leading isolate with 70.2% (198/282) specimens reporting the growth, followed by *Klebsiella pneumoniae* 19.8% (56/282), *P. aeruginosa* 4.25% (12/282), *Citrobacter spp* 1.06% (03/282), *Proteus spp* 0.7% (02/282). Among gram positive uropathogens, majority were *Coagulase negative Staphylococcus*, followed by *Staphylococcus aureus*, *Enterococcus* and *Candida* spp.

Uropathogenic *Escherichia coli* (UPEC) from the gut are the cause of 80–85% of community-acquired urinary tract infections (Etienne *et al.*, 2014; Schito *et al.*, 2009). In uncomplicated UTIs, *E.coli* is the leading organism, whereas in complicated UTIs the bacterial spectrum is much broader including Gram-negative and Gram-positive and often multidrug resistant organisms.

Research studies suggest that P fimbriae contribute as virulence factors of *E. coli* strains to cause UTI, especially the more clinically severe forms. As per various researches, leading organisms involved in uncomplicated UTIs, after UPEC are *Klebsiella pneumoniae*, *Staphylococcus saprophyticus*, *Enterococcus faecalis*, group B *Streptococcus*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Candida* spp (Foxman *et al.*, 2014, Nielubowicz *et al.*, 2010, and Kline *et al.*, 2011).

In the present study, gram negative isolates showed least resistance to Imipenem (12%), followed by Nitrofurantoin (24%), Gentamicin (28%) Piperacillin Tazobactam (36%).

A significant amount of resistance was documented to antibiotics like Norfloxacin (80%), Cefazolin (76%), and Cotrimoxazole (68%) Ciprofloxacin (64%), Tetracycline (60%). In the current study, overall 40.2% (109/271) gram negative isolates were detected positive for ESBL production. *E. coli* was the predominant 77.06% (84/109) ESBL producing isolate. ESBL production has been reported ranging from 38.9% (Rishabh *et al.*, 2018), 39.5% (Vasumathi *et al.*, 2016), 40% (Babypadmini *et al.*, 2004), 42% (Babek *et al.*, 2012), 44.5% (Saeide *et al.*, 2014) which is similar to our findings. However, even higher incidence of 58% and 84.6% has been reported by Mathur *et al.*, (2002) & Rejitha *et al.*, (2014) respectively (Table 5).

Table.1 Gender wise and department wise distribution of urine specimens

	No. of specimens	Culture positive (n=282)
Male	82	78 (27.6%)
Female	224	204 (72.4%)
Total	306	282
OPD and IPD distribution of urine specimens		
	No. of specimens	Culture positive (n=282)
OPD	232	196 (69.5%)
IPD	74	86 (30.5%)
Total	306	282

Table.2 Distribution of uropathogens (Total isolates n= 282)

S. no	Organism isolated	No. of isolates	ESBL positive**
Gram negative (n=271)			
1.	<i>Escherichia coli</i>	198	84
2.	<i>Klebsiella spp</i>	56	22
3.	<i>Pseudomonas aeruginosa</i>	12	02
4.	<i>Citrobacter spp</i>	03	01
5.	<i>Proteus spp</i>	02	-----
Total isolates		271	109
Gram positive uropathogenic isolates (n=11)			
1.	<i>Staphylococcus aureus</i>	03	
2.	<i>Coagulase negative Staphylococcus (CoNS)</i>	05	
3.	<i>Candida spp</i>	02	
4.	<i>Enterococcus</i>	01	
Total urinary isolates			282

** ESBL not tested in Gram positive isolates

Table.3 Antimicrobial susceptibility pattern of gram negative urinary pathogens (n=271)

S. no	Antimicrobial	Sensitive (%)	Resistant (%)
1.	Norfloxacin 10 µg	20%	80%
2.	Cefazolin 30µg	24%	76%
3.	Cotrimaxazole 25 µg	32%	68%
4.	Ciproflaxacin 5µg	36%	64%
5.	Tetracycline 30ug	40%	60%
6.	Ceftriaxone 30 µg	54%	46%
7.	Ceftazidime 30µg	58%	42%
8.	Piperacillin-Tazobactam 100/10µg	64%	36%
9.	Gentamicin 10 µg	72%	28%
10.	Nitrofurantoin 300 µg	76 %	24 %
11.	Imipenem 10µg	88%	12%



Table.4 Antimicrobial Sensitivity of ESBL isolates (n=109)

S. no	Antimicrobial	Sensitive ESBL isolates (%)
1.	Imipenem 10µg	90 (82.5)
2.	Nitrofurantoin 300 µg	85 (77.9%)
3.	Piperacillin-Tazobactam 100/10µg	78 (71.5%)

Table.5 Comparison of community vs hospital ESBL isolates

ESBL production	Community acquired UTI	Hospital acquired UTI	Total
ESBL positive	31	78	109
ESBL negative	165	08	173
Total	196	86	282

The p value is <0.00001. The result is significant at p <0.05 by Chi square test



The local epidemiology, study population, patterns and protocols of antibiotic usage have a remarkable influence on differences in the ESBL pattern documented in the above mentioned studies.

In the present study, hospital ESBL isolates i.e 71.5% (78/109) were significantly higher than community ESBL isolates 28.5% (31/109). Higher incidences of ESBL uropathogens in hospitalized patients as compared to community settings are reported by Babypadmini *et al.*, (2004) and Babek *et al.*, (2012). Factors predisposing to emergence and transmission of ESBL organisms include the duration of exposure to broad spectrum antibiotics, length of stay in hospital, severity of underlying illness, use of invasive devices such as urinary catheters, or surgery. (Flaherty *et al.*, 1996) It is well known that ESBL producing bacteria cause infections in hospitalized patients but nowadays ESBL isolates are reported from community infections also (Nesher *et al.*, 2007). Mahesh *et al.*, (2010) and Taneja *et al.*, (2008) reported higher ESBL isolates around 56.2% and 36.5% from community setting as compared to our study.

ESBL producing organisms causing community UTI can lead to treatment failure or delayed clinical response. Furthermore, these isolates being multidrug resistant, antimicrobials like amino glycosides, quinolones and cotrimoxazole are often ineffective clinically (Auer *et al.*, 2010) Carbapenems are generally considered the drug of choice for the treatment of ESBL infections (Pitout *et al.*, 2008; Rodriguez *et al.*, 2012). Therefore, on basis of above considerations, in the present study we have analyzed sensitivity of ESBL producers for imipenem, nitrofurantoin and piperacillin tazobactam which can retain their activity even against ESBL pathogens. In the present study 82.5% (90/109) ESBL producing

isolates were sensitive to Imipenem. Also, as per the results in the current study, nitrofurantoin can also be considered as a good treatment option, the resistance being less documented. The findings are in consensus with studies done by Bajpai *et al.*, (2014), Sasirekha *et al.*, (2013), and Khameneh *et al.*, (2009) which have reported nitrofurantoin as a suitable agent for the first line treatment of the community acquired UTI.

Piperacillin-tazobactam (PTZ) is one of the most frequently utilized agents for empiric gram negative bacterial coverage and retains activity against ESBL producers.

Furthermore, antimicrobial stewardship practices encourage the use of carbapenem sparing treatment regimens for infections due to ESBL gram negative infections. Results from this study suggest that PTZ is effective in the treatment of urinary tract infection caused by ESBL when the in vitro test indicates susceptibility. Randomized controlled trial by Seo *et al.*, (2017) also confirms effectiveness of PTZ in ESBL producing uropathogenic *E. coli*.

ESBL uropathogens are isolated from community as well as hospital settings. ESBL producers generally do not respond to the usually prescribed empirical therapy. Presently, alternative antimicrobial therapy to treat ESBL positive UTI on outpatient basis is limited. Imipenem was the most effective drug; however, it should not be administered as empirical drug unless infection is life threatening, as carbapenems are considered the drug of last resort. But alternatives for the treatment of ESBL-producing bacteria are urgently needed to suppress the emergence of carbapenem resistance. Results from this study suggest that Piperacillin-tazobactam, nitrofurantoin, are also effective in the treatment of UTI caused by ESBL pathogens.

References

- Aggarwal R, Chaudhary U, Sikka R. Detection of extended spectrum β -lactamase production among uropathogens. *J Lab Physicians* 2009; 1:7-1014.
- Amdekar S, Singh V, Singh DD. Probiotic therapy: immunomodulating approach toward urinary tract infection. *Current microbiology* 2011; 63 (5): 484–90.
- Auer S, Wojna A, Hell M. Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum beta-Lactamase Producing *Escherichia coli*. *Antimicro Agents Chemo* 2010, 54:4006-8.
- Babak Pourakbari, Farzad Ferdosian, Shima Mahmoudi, Mostafa Teymuri, Farah Sabouni, Hossein Heydari *et al.*, Increase resistant rates and ESBL production between *E. coli* isolates causing Urinary Tract Infection in young patients from Iran. *Brazilian Journal of Microbiology*, 2012: 766-769
- Babypadmini S, Appalaraju B. Extended spectrum β lactamases in urinary isolates of *Escherichia coli* and *Klebsiella pneumoniae* - Prevalence and susceptibility pattern in a tertiary care hospital. *Indian J Med Microbiol.* 2004; 22:172–4.
- Bagshaw SM, Laupland, KB. Epidemiology of intensive care unit-acquired urinary tract infections. *Current Opinion in Infectious Diseases* 2006; 19 (1): 67–71.
- Bajpai, T., Pandey, M., Varma, M. and Bhatambare, G. S. Prevalence of extended spectrum beta-lactamase producing uropathogens and their antibiotic resistance profile in patients visiting a tertiary care hospital in central India: Implications on empiric therapy. *Indian J. Pathol. Microbiol* 2014.57, 407–12.
- Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disc method. *Am. J. Clin. Pathol.* 1966; 45:493–496
- Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing; CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
- Collee JG, Miles RS, Watt B. Mackie & McCartney's Practical Medical Microbiology 14th Ed. In: JG Collee, AG Fraser, BP Marmion, A Simmons, Editors. Churchill Livingstone: Indian Reprint; 2008
- Daniele Minardi Gianluca d'Anzeo Daniele Cantoro Alessandro Conti Giovanni Muzzonigro. Urinary tract infections in women: etiology and treatment options. *International Journal of General Medicine* 2011; 4: 333–343
- Dash M, Padhi S, Mohanty I, Panda P, Parida B. Antimicrobial resistance in pathogens causing urinary tract infections in a rural community of Odisha, India *J Family Community Med* 2013; 20(1): 20-6.
- Etienne M, Lefebvre E, Frebourg N, Hamel H, Pestel-Caron M, Caron F. Antibiotic treatment of acute uncomplicated cystitis based on rapid urine test and local epidemiology: lessons from a primary care series. *BMC Infect Dis.* 2014; 14:1–8.
- Flaherty JP, Weinstein RA. Nosocomial infection caused by antibiotic-resistant organisms in the intensive-care unit. *Infect Control Hosp Epidemiol.* 1996; 17:236–248.
- Flores-Mireles AL; Walker JN; Caparon M; Hultgren, SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nature Reviews. Microbiology* 2015; 13(5): 269–84.

- Forbes BA, Sahm DF, Weissfield AS. Bailey and Scotts Diagnostic Microbiology. 12th ed. USA: Mosby Elsevier; 2007.
- Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am.* 2014; 28:1–13.
- Gupta, K., T. M. Hooton, K. G. Naber *et al.*, International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious diseases society of America and the European society for microbiology and infectious diseases, *Clinical Infectious Diseases* 2011; 52(5):103–120
- Hooton, T. M., S. F. Bradley, D. D. Cardenas *et al.*, Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the infectious diseases society of America, *Clinical Infectious Diseases* 2010; 50(5): 625–663
- Khameneh, Z R. and Afshar, A. T. Antimicrobial susceptibility pattern of urinary tract pathogens. *Saudi J. kidney Dis. Transplant* 2009; 20: 251–3.
- Kline KA, Schwartz DJ, Lewis WG, Hultgren SJ, Lewis AL. Immune activation and suppression by group B Streptococcus in a murine model of urinary tract infection. *Infect Immun.* 2011; 79:3588–3595.
- Mahesh E, Ramesh D, Indumathi VA, *et al.*, Risk Factors for Community Acquired Urinary Tract Infection caused by ESBL-producing Bacteria. *JIACM* 2010; 11:271-6.
- Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum β -lactamase producing gram negative bacteria in a tertiary care hospital. *Indian J Med Res.* 2002; 115:153–7.
- Mitsumori K, Terai A, Yamamoto S, Yoshida O. Virulence characteristics and DNA fingerprints of *Escherichia coli* isolated from women with acute uncomplicated pyelonephritis. *J Urol.* 1997; 158(6):2329–2332
- Mukherjee M, Basu S, Mukherjee SK, Majumder M. Multidrug-resistance and extended spectrum beta-lactamase production in uropathogenic *E. coli* which were isolated from hospitalized patients in Kolkata, India. *J Clin Diagn Res* 2013; 7:449-53.
- Naiemi NA, Murk JL, Savelkoul PH, Vandembroucke-Grauls CM, Debets Ossenkopp YJ. Extended-spectrum beta-lactamases screening agar with AmpC inhibition. *Eur J Clin Microbiol Infect Dis* 2009; 28:989-90
- Neal DE Jr. Complicated urinary tract infections. *Urol Clin North Am* 2008; 35: 13–22
- Nesher L, Novack V, Riesenber F, *et al.*, Regional community-acquired urinary tracts in Israel; diagnosis, pathogens, and antibiotics guidelines adherence: A prospective study. *International J Infect Dis* 2007; 11:245-50.
- Newell A, P. Riley, and M. Rodgers, Resistance patterns of urinary tract infections diagnosed in a genitourinary medicine clinic. *International Journal of STD and AIDS* 2000; 11(8): 499–500.
- Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. *Urol Clin North Am* 2008; 35 (1): 1–12
- Nielubowicz GR, Mobley HL. Host–pathogen interactions in urinary tract infection. *Nature Rev Urol.* 2010; 7:430–441.
- Pitout JDD, Laupland KB. Extended-spectrum β -lactamase–producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis.* 2008; 8:159-166.

- Prakash D, Saxena RS. Distribution and Antimicrobial Susceptibility Pattern of Bacterial Pathogens Causing Urinary Tract Infection in Urban Community of Meerut City, India. *ISRN Microbiology*. 2013; 2013:749629.
- Qi, C., V. Pilla, J. H. Yu, and K. Reed. Changing prevalence of *Escherichia coli* with CTX-M-type extended-spectrum β -lactamases in outpatient urinary *E. coli* between 2003 and 2008. *Diagnostic Microbiology and Infectious Disease* 2010; 67(1):87–91.
- Rejitha IM, G Sucilathangam, G Velvizhi. Urinary Tract Infection (UTI) In the Elderly - A Clinical and Microbiological Study. *Indian Journal of Applied Research Medical Science*, April 2014; 4(4): 465-467.
- Rishabh Rajput and Surendra Sarsaiya. Significance of Regional Antibiogram and MDR of ESBL Producing Uropathogens Infecting Non-hospitalized Patients: Gurugram. *Int.J.Curr.Microbiol.App.Sci* 2018; 7(2): 1114-1126
- Rodriguez-Bano J, Navarro MD, Retamar P, *et al.*, β -lactam/ β -lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β -lactamase-producing *Escherichia coli*: a post hoc analysis of prospective cohorts. *Clin Infect Dis*. 2012; 54(2):167-174.
- Saeide Saeidi, Mehdi Ghamgosha, Ramezan Ali Taheri, Yasub Shiri, Mahmood Solouki, Kazem Hassanpour, Gholamreza Farnoosh. Phenotypic and genotypic detection of extended-spectrum β -lactamase (ESBL) producing *Escherichia coli* isolated from urinary tract infections in Zabol, Iran. *Journal of Coastal Life Medicine* 2014; 2(9): 732-737
- Salvatore S, Cattoni E, Siesto G, Serati M, Sorice P, Torella M. Urinary tract infections in women. *European journal of obstetrics, gynecology, and reproductive biology* 2011; 156 (2): 131–6
- Sanchez, G. V., R. N. Master, J. A. Karlowsky, and J. M. Bordon. In vitro antimicrobial resistance of urinary *Escherichia coli* isolates among U.S. outpatients from 2000 to 2010. *Antimicrobial Agents and Chemotherapy* 2012; 56(4): 2181–2183.
- Sasirekha, B. Prevalence of ESBL, AmpC β -lactamases and MRSA among uropathogens and its antibiogram. *EXCLI J* 2013; 12:81–8
- Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, *et al.*, The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. *Int J Antimicrob Agents*. 2009; 34:407–13.
- Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. *J Infect Dis*. 2000; 182(4):1177–1182.
- Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, Uh Y, Kim HS, Song W. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *BMC Infect Dis*. 2017 Jun 7; 17(1):404
- Sievert DM, Ricks P, Edwards JR, *et al.*, Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. *Infect Control Hosp Epidemiol* 2013; 34 (1): 1–14.

- Taneja N, Rao P, Arora J, *et al.*, Occurrence of ESBL & Amp-C β -lactamases & susceptibility to newer antimicrobial agents in complicated UTI. *Indian J Med Res* 2008; 127: 85-8.
- Vasumathi A, Thenmozhi Valli PR, Senthamarai S. Extended Spectrum β Lactamase (ESBL) Producing Uropathogens in the Intensive Care Unit in A Tertiary Care Hospital, Tamilnadu *IOSR-JDMS* 2016;15 (2): 66-68
- Wilson, M. L., and L. Gaido. Laboratory diagnosis of urinary tract infections in adult patients,” *Clinical Infectious Diseases* 2004; 38(8): 1150–1158.
- Yamamoto S, Tsukamoto T, Terai A, Kurazono H, Takeda Y, Yoshida O. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by *Escherichia coli*. *J Urol*. 1997; 157(3):1127–1129.
- Yazdi M, Nazemi A, Mirinargasi M, Jafarpour M, Sharifi SH. Genotypic versus Phenotypic methods to detect extended-spectrum β lactamases (ESBLs) in uropathogenic *Escherichia coli*. *Ann Biol Res* 2012; 3:2454-8.

How to cite this article:

Gitanjali Kailas Badave, Qader Ahmed Jalily and Sasikala, G. 2018. A Study of Uropathogenic ESBL Producing Gram Negative Bacilli in a Teaching Hospital. *Int.J.Curr.Microbiol.App.Sci*. 7(09): 919-929. doi: <https://doi.org/10.20546/ijemas.2018.709.111>